FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019814452> ?p ?o ?g. }

• W2019814452 endingPage "106" @default.
• W2019814452 startingPage "86" @default.
• W2019814452 abstract "THE RISKS OF ORAL CONTRACEPTIVES AND ESTROGEN REPLACEMENT THERAPY FREDRIC L. COE andJOAN H. PARKS* So many millions ofwomen use oral contraceptive pills (OCP) or estrogen replacement (ERT) after menopause that all side effects matter, especially any that promote major illnesses, such as cancer, heart attack, or stroke. The risks of OCP and ERT have been studied rather well, but not everyone understands what is known, partly because published reports are scattered and statistically elaborate, and partly because some have contradicted each another and some are clearly wrong. We offer our summary of the main studies linking cancer, heart attack, stroke, and venous thromboembolism that we believe clearly define the serious risks of OCP and ERT. How Risk Is Measured If women who use OCP or ERT are matched, somehow, with women who do not, and the two cohorts are observed over years, one can count the occurrences of diseases among the users and the controls and estimate risk. Because each woman is observed only so long, and women are changeable—they stop OCP, or start it, or become pregnant—each contributes woman-years to categories such as never user, past user, current user. The tally of disease occurrences per woman-year is a mosaic pieced together of years from many women, each one contributing time as her habits have dictated. The cohorts must be matched in age, by behaviors that affect risk such as smoking, the timing and number of pregnancies, and by matters of fate, like family history. We will tell you about eight cohort studies, one of them of the most specialized type, a random-allocation, double-blind drug trial. Work supported by NIH POl 33949. *Nephrology Program, University of Chicago, Pritzker School of Medicine, Chicago, Illinois 60637.© 1989 by The University of Chicago. AU rights reserved. 003 1 -5982/90/330 1-0650$0 1 .00 86 I Fredric L. Coe andJoan H. Parks · Risks ofEstrogen Therapy The common alternative to cohorts uses case controls. Investigators cull out every case of a disease as it is diagnosed in some region of the country or in a cluster of hospitals. By some device, they select two matching women for each case, from the same locale or group of hospitals , or clinics, one of whom does not have the disease but is like the woman who does in age, risk factors, and all other ways possible. Among the cases and the controls, how many use OCP, or ERT, or have used one or both? If cases use OCP or ERT more than controls, or have used OCP or ERT, OCP or ERT may be the guilty party; why else be more frequent in cases if the controls were chosen fairly? How you express risk depends on study design. Using cohorts, you measure new incidents of disease per woman per year, the incidence rate. Risk is the ratio of incidence rates of—let us say—OCP users or past users to rates of nonusers or never users. For case control, risk is inferred from enrichment; the greater the frequency of, for example, OCP use in cases versus controls, the greater the risk. The actual result is a risk ratio that is based on the frequency rates and complicated computation . Guilt is by association. What Are OCP and ERT? All OCPs used today contain an estrogen and a progestogen. Normally , the ovaries produce estradiol, which is the most potent natural hormone that can cause the estrogenic response: uterine growth, thickening of vaginal mucosa, thinning of cervical mucus, development of the ductal system of the breasts, and female characteristics ofhair and body fat distribution and skin texture. The other estrogen in blood, estrone, is made mainly by other tissues, from androstenedione, the immediate precursor of testosterone. Twenty-nine of 38 current preparations [1] use ethinyl estradiol, 20-50 µg daily; this compound is estradiol bearing an added ethinyl group at carbon-17. The rest use mestranol , identical except that a methoxy group replaces a hydroxyl group at carbon-3. The physiologic progestogen is progesterone, produced mainly by the ovarian corpus luteum. Progestational effects of the hormone prepare the uterine lining for implantation of the fertilized egg, inhibit uterine contractions, and stimulate..." @default.
• W2019814452 created "2016-06-24" @default.
• W2019814452 creator A5015891160 @default.
• W2019814452 creator A5024762736 @default.
• W2019814452 date "1989-01-01" @default.
• W2019814452 modified "2023-09-25" @default.
• W2019814452 title "The Risks of Oral Contraceptives and Estrogen Replacement Therapy" @default.
• W2019814452 cites W1558498964 @default.
• W2019814452 cites W1680009388 @default.
• W2019814452 cites W1977693409 @default.
• W2019814452 cites W1994185207 @default.
• W2019814452 cites W2011042831 @default.
• W2019814452 cites W2013765695 @default.
• W2019814452 cites W2019197306 @default.
• W2019814452 cites W2023989263 @default.
• W2019814452 cites W2030560771 @default.
• W2019814452 cites W2033238018 @default.
• W2019814452 cites W2059738685 @default.
• W2019814452 cites W2074289506 @default.
• W2019814452 cites W2083134352 @default.
• W2019814452 cites W2084640848 @default.
• W2019814452 cites W2085308886 @default.
• W2019814452 cites W2094822609 @default.
• W2019814452 cites W2120955256 @default.
• W2019814452 cites W2127282672 @default.
• W2019814452 cites W2290912766 @default.
• W2019814452 cites W2303726387 @default.
• W2019814452 cites W2329870856 @default.
• W2019814452 cites W2335854637 @default.
• W2019814452 cites W2341031326 @default.
• W2019814452 cites W2414845608 @default.
• W2019814452 cites W284109511 @default.
• W2019814452 cites W3012714900 @default.
• W2019814452 cites W2323251034 @default.
• W2019814452 doi "https://doi.org/10.1353/pbm.1990.0026" @default.
• W2019814452 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2689999" @default.
• W2019814452 hasPublicationYear "1989" @default.
• W2019814452 type Work @default.
• W2019814452 sameAs 2019814452 @default.
• W2019814452 citedByCount "5" @default.
• W2019814452 crossrefType "journal-article" @default.
• W2019814452 hasAuthorship W2019814452A5015891160 @default.
• W2019814452 hasAuthorship W2019814452A5024762736 @default.
• W2019814452 hasConcept C126322002 @default.
• W2019814452 hasConcept C127413603 @default.
• W2019814452 hasConcept C159110408 @default.
• W2019814452 hasConcept C160050368 @default.
• W2019814452 hasConcept C2777164284 @default.
• W2019814452 hasConcept C2778562196 @default.
• W2019814452 hasConcept C2779076696 @default.
• W2019814452 hasConcept C2779134260 @default.
• W2019814452 hasConcept C2779279991 @default.
• W2019814452 hasConcept C2780159708 @default.
• W2019814452 hasConcept C2780645631 @default.
• W2019814452 hasConcept C2908647359 @default.
• W2019814452 hasConcept C29456083 @default.
• W2019814452 hasConcept C2986817661 @default.
• W2019814452 hasConcept C3020211606 @default.
• W2019814452 hasConcept C3020687571 @default.
• W2019814452 hasConcept C512399662 @default.
• W2019814452 hasConcept C71924100 @default.
• W2019814452 hasConcept C78519656 @default.
• W2019814452 hasConcept C81603835 @default.
• W2019814452 hasConcept C99454951 @default.
• W2019814452 hasConceptScore W2019814452C126322002 @default.
• W2019814452 hasConceptScore W2019814452C127413603 @default.
• W2019814452 hasConceptScore W2019814452C159110408 @default.
• W2019814452 hasConceptScore W2019814452C160050368 @default.
• W2019814452 hasConceptScore W2019814452C2777164284 @default.
• W2019814452 hasConceptScore W2019814452C2778562196 @default.
• W2019814452 hasConceptScore W2019814452C2779076696 @default.
• W2019814452 hasConceptScore W2019814452C2779134260 @default.
• W2019814452 hasConceptScore W2019814452C2779279991 @default.
• W2019814452 hasConceptScore W2019814452C2780159708 @default.
• W2019814452 hasConceptScore W2019814452C2780645631 @default.
• W2019814452 hasConceptScore W2019814452C2908647359 @default.
• W2019814452 hasConceptScore W2019814452C29456083 @default.
• W2019814452 hasConceptScore W2019814452C2986817661 @default.
• W2019814452 hasConceptScore W2019814452C3020211606 @default.
• W2019814452 hasConceptScore W2019814452C3020687571 @default.
• W2019814452 hasConceptScore W2019814452C512399662 @default.
• W2019814452 hasConceptScore W2019814452C71924100 @default.
• W2019814452 hasConceptScore W2019814452C78519656 @default.
• W2019814452 hasConceptScore W2019814452C81603835 @default.
• W2019814452 hasConceptScore W2019814452C99454951 @default.
• W2019814452 hasIssue "1" @default.
• W2019814452 hasLocation W20198144521 @default.
• W2019814452 hasLocation W20198144522 @default.
• W2019814452 hasOpenAccess W2019814452 @default.
• W2019814452 hasPrimaryLocation W20198144521 @default.
• W2019814452 hasRelatedWork W2006619682 @default.
• W2019814452 hasRelatedWork W2018583822 @default.
• W2019814452 hasRelatedWork W2024451992 @default.
• W2019814452 hasRelatedWork W2272170328 @default.
• W2019814452 hasRelatedWork W2325385507 @default.
• W2019814452 hasRelatedWork W2400578820 @default.
• W2019814452 hasRelatedWork W2405368206 @default.
• W2019814452 hasRelatedWork W2431574754 @default.

• next